{"chain_id": "chain_000000", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5948914", "num_turns": 4, "model": "gpt-5.2", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5948914, is the following pharmacogenomic claim supported or contradicted: Genotypes GT + TT are not associated with overall survival when treated with gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported.** In this NSCLC cohort treated with gemcitabine-based chemotherapy, the study did **not** find a significant association between **overall survival (OS)** and the **HELB T980I** variant when comparing **CT/TT vs CC** (analogous to GT/TT vs GG): OS HR 1.23, *P* = 0.412 (Table 2)."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2231142 and gemcitabine in Disease:Non-Small Cell Lung Carcinoma (PMCID PMC5948914), what p-value was reported for this association?", "answer": "= 0.080", "response": "For **rs2231142 (ABCG2 Q141K)** in **NSCLC** treated with **gemcitabine-based chemotherapy**, the reported p-value for the survival association was:\n\n- **Progression-free survival (PFS), multivariate (adjusted): p = 0.007** (CA/AA vs CC; Table 2)\n\n(For reference, **overall survival (OS)** multivariate adjusted **p = 0.080**.)"}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "true"}]}
{"chain_id": "chain_000001", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC11732454", "num_turns": 4, "model": "gpt-5.2", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC11732454, is the following pharmacogenomic claim supported or contradicted: HLA-A *31:03 is associated with decreased likelihood of Stevens-Johnson Syndrome when treated with carbamazepine, lamotrigine or phenytoin. Answer one of: supported, contradicted.", "answer": "supported", "response": "supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of HLA-A*31:03 and carbamazepine, lamotrigine, phenytoin in Toxicity (PMCID PMC11732454), what confidence interval was reported?", "answer": "0.13\u20130.27", "response": "For **HLA-A*31:03 and SJS** in PMCID **PMC11732454**, the reported confidence interval was **95% CI: 0.13\u20130.27** (Table 5; OR 0.19)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "true"}]}
{"chain_id": "chain_000002", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4640545", "num_turns": 4, "model": "gpt-5.2", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4640545, is the following pharmacogenomic claim supported or contradicted: Genotype CC is not associated with metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2298771 and carbamazepine in Disease:Epilepsy (PMCID PMC4640545), what p-value was reported for this association?", "answer": "> 0.05", "response": "No p-value was reported for the rs2298771 (SCN1A c.3184A>G) association with carbamazepine pharmacokinetic/metabolism measures in this paper; it was described as not significant (Table 2) without specific p-values."}, {"turn": 4, "reasoning_type": "counterfactual_evaluation", "question": "Would this association remain significant at alpha = 0.01? Answer true or false.", "answer": false, "response": "false"}]}
{"chain_id": "chain_000003", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC4177494", "num_turns": 4, "model": "gpt-5.2", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC4177494, is the following pharmacogenomic claim supported or contradicted: Genotypes GG + GT is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT. Answer one of: supported, contradicted.", "answer": "supported", "response": "supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs8099917 and peginterferon alfa-2a, peginterferon alfa-2b, ribavirin in Disease:Hepatitis C virus infection (PMCID PMC4177494), what OR was reported?", "answer": "7.9", "response": "OR = 7.9 (95% CI: 1.99\u201331.18) for rs8099917 TG/GG (G-allele carriers) predicting null-response (HCV RNA decline <1 log10 at week 4) vs TT."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": true, "response": "true"}]}
{"chain_id": "chain_000004", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC7351433", "num_turns": 4, "model": "gpt-5.2", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC7351433, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele T. Answer one of: supported, contradicted.", "answer": "supported", "response": "supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs1801131 and methotrexate in Other:Acute lymphoblastic leukemia (PMCID PMC7351433), what p-value was reported for this association?", "answer": "> 0.05", "response": "No statistically significant association was reported between **MTHFR rs1801131** and **48-hour plasma methotrexate levels** in PMCID **PMC7351433** (the paper does **not** provide a p-value for this specific MTX concentration association; it is reported as **P > 0.05** / not significant)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "false"}]}
{"chain_id": "chain_000005", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC3909071", "num_turns": 4, "model": "gpt-5.2", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC3909071, is the following pharmacogenomic claim supported or contradicted: Allele T is associated with increased risk of Heroin Dependence when exposed to heroin as compared to allele C. Answer one of: supported, contradicted.", "answer": "supported", "response": "supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs13242038 and heroin in Other (PMCID PMC3909071)?", "answer": 619, "response": "619 controls were included."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "true"}]}
{"chain_id": "chain_000006", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5519037", "num_turns": 4, "model": "gpt-5.2", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5519037, is the following pharmacogenomic claim supported or contradicted: Genotypes CT + TT are not associated with concentrations of everolimus in women with Breast Neoplasms as compared to genotype CC. Answer one of: supported, contradicted.", "answer": "supported", "response": "supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs776746 and everolimus in Disease:Breast Neoplasms (PMCID PMC5519037), what p-value was reported for this association?", "answer": "> 0.05", "response": "No p-value was reported for the rs776746 (CYP3A5)\u2013everolimus concentration association in this paper (they only state it was not significant)."}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Is this finding statistically significant at alpha = 0.05? Answer true or false.", "answer": false, "response": "false"}]}
{"chain_id": "chain_000007", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC5207665", "num_turns": 4, "model": "gpt-5.2", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC5207665, is the following pharmacogenomic claim supported or contradicted: Allele A is not associated with response to bevacizumab in women with Breast Neoplasms as compared to allele G. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Contradicted.** In this paper, the *ANGPT2* SNP **rs2515462** (minor allele **A** vs major allele **G**) showed a significant association with pathologic complete response (pCR) to bevacizumab-containing neoadjuvant therapy (adjusted OR 4.31, raw *P* = 0.011), indicating allele **A** *is* associated with response compared to allele **G**."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many controls were included in the study of rs17577 and bevacizumab in Disease:Breast Neoplasms (PMCID PMC5207665)?", "answer": 33, "response": "0"}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study controls? Answer true or false.", "answer": true, "response": "false"}]}
{"chain_id": "chain_000008", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC1689719", "num_turns": 4, "model": "gpt-5.2", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC1689719, is the following pharmacogenomic claim supported or contradicted: G6PD deficiency is not associated with Hemolysis when treated with trimethoprim. Answer one of: supported, contradicted.", "answer": "supported", "response": "supported"}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "functional_assay"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "How many cases were included in the study of G6PD deficiency and trimethoprim in Toxicity (PMCID PMC1689719)?", "answer": 8, "response": "2 cases"}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does this meet the dataset minimum of N \u2265 30 for study cases? Answer true or false.", "answer": false, "response": "false"}]}
{"chain_id": "chain_000009", "chain_family": "A_claim\u2192modality\u2192stat\u2192eval", "pmcid": "PMC2850440", "num_turns": 4, "model": "gpt-5.2", "turns": [{"turn": 1, "reasoning_type": "claim_verification", "question": "Based on PMCID PMC2850440, is the following pharmacogenomic claim supported or contradicted: Allele G is not associated with increased risk of Crohn Disease. Answer one of: supported, contradicted.", "answer": "supported", "response": "**Supported.** In the Crohn disease analysis, SNPs with minor allele **G** (e.g., rs2542151) showed no significant association with Crohn disease (allelic p = 0.68 in European ancestry; p = 0.82 in European+unknown), indicating **G was not associated with increased risk** in this study."}, {"turn": 2, "reasoning_type": "evidence_provenance_localization", "question": "What type of evidence does this annotation represent: clinical association or functional assay? Answer one of: clinical_association, functional_assay.", "answer": "clinical_association", "response": "clinical_association"}, {"turn": 3, "reasoning_type": "statistical_extraction", "question": "For the study of rs2542151 (PMCID PMC2850440), what OR was reported?", "answer": "1.0834", "response": "For **rs2542151** (Crohn disease), the reported **allelic OR** was:\n\n- **OR = 1.0834** (European ancestry, definite cases; 95% CI 0.74\u20131.58)"}, {"turn": 4, "reasoning_type": "objective_evaluation", "question": "Does the confidence interval for the OR exclude the null value of 1.0? Answer true or false.", "answer": false, "response": "false"}]}
